Intervention

topotecan hydrochloride

ClinicalTrials.gov intervention label

Clinical trials28
Recruiting0
Common conditions25
Lead sponsors shown14

Clinical trials

28 shown
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung CancerNCT01803269 · 2013-01-16
TERMINATED
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00828139 · 2009-05-01
COMPLETED
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid TumorsNCT00521144 · 2007-08-01
COMPLETED
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic ChemotherapyNCT00365547 · 2006-09-01
COMPLETED
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid TumorsNCT00112619 · 2005-08-01
TERMINATED
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung CancerNCT00098956 · 2005-01-01
COMPLETED
Bortezomib and Topotecan in Treating Patients With Advanced Solid TumorsNCT00388089 · 2004-12-01
COMPLETED
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung CancerNCT00087048 · 2004-04-01
TERMINATED
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung CancerNCT00287963 · 2004-02-01
COMPLETED
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate CancerNCT00084565 · 2003-11-01
WITHDRAWN
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung CancerNCT00028925 · 2001-11-01
COMPLETED
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00025272 · 2001-11-01
COMPLETED
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00041015 · 2001-09-01
COMPLETED
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00033696 · 2001-09-01
COMPLETED
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00006012 · 2001-02-01
COMPLETED
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous TreatmentNCT00005811 · 2000-04-01
COMPLETED
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast CancerNCT00006032 · 2000-03-01
TERMINATED
Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung CancerNCT00004055 · 1999-11-01
COMPLETED
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00006374 · 1999-10-01
WITHDRAWN
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung CancerNCT00004137 · 1999-10-01
COMPLETED
Topotecan in Treating Patients With Relapsed Small Cell Lung CancerNCT00003917 · 1999-03-01
COMPLETED
Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00003812 · 1999-03-01
COMPLETED
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.NCT00003943 · 1998-09-01
COMPLETED
Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung CancerNCT00003281 · 1998-04-01
COMPLETED
Combination Chemotherapy in Treating Patients With Small Cell Lung CancerNCT00004186 · 1996-12-01
COMPLETED
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or LymphomaNCT00002625 · 1995-03-01
COMPLETED
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung CancerNCT00002537 · 1993-09-01
COMPLETED
Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid TumorsNCT00004979
COMPLETED

Common conditions

Lung Cancer19Recurrent Small Cell Lung Cancer4Extensive Stage Small Cell Lung Cancer3Unspecified Adult Solid Tumor, Protocol Specific3Carcinoma of Unknown Primary2Lymphoma2Unspecified Childhood Solid Tumor, Protocol Specific2AIDS-related Diffuse Large Cell Lymphoma1AIDS-related Diffuse Mixed Cell Lymphoma1AIDS-related Diffuse Small Cleaved Cell Lymphoma1AIDS-related Immunoblastic Large Cell Lymphoma1AIDS-related Lymphoblastic Lymphoma1AIDS-related Peripheral/Systemic Lymphoma1AIDS-related Primary CNS Lymphoma1AIDS-related Small Noncleaved Cell Lymphoma1Brain and Central Nervous System Tumors1Breast Cancer1Childhood Diffuse Large Cell Lymphoma1Childhood Immunoblastic Large Cell Lymphoma1Drug/Agent Toxicity by Tissue/Organ1Esophageal Cancer1HIV-associated Hodgkin Lymphoma1Leptomeningeal Metastases1Leukemia1Prostate Cancer1

Leading sponsors

Alliance for Clinical Trials in Oncology6National Cancer Institute (NCI)6Case Comprehensive Cancer Center4Fox Chase Cancer Center2H. Lee Moffitt Cancer Center and Research Institute1Jonsson Comprehensive Cancer Center1Masonic Cancer Center, University of Minnesota1Medical University of South Carolina1Pediatric Brain Tumor Consortium1SWOG Cancer Research Network1University of Alabama at Birmingham1University of California, Davis1University of Chicago1Wake Forest University Health Sciences1

Trial status mix

COMPLETED22
TERMINATED4
WITHDRAWN2

Phase mix

PHASE221
PHASE19
PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.